Critical Contrast: IN8bio (NASDAQ:INAB) & Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR) and IN8bio (NASDAQ:INAB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Insider & Institutional Ownership

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Structure Therapeutics and IN8bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	1	12	3	2.89
IN8bio	1	1	1	0	2.00

Structure Therapeutics presently has a consensus price target of $110.55, indicating a potential upside of 113.65%. IN8bio has a consensus price target of $4.00, indicating a potential upside of 196.30%. Given IN8bio’s higher probable upside, analysts clearly believe IN8bio is more favorable than Structure Therapeutics.

Profitability

This table compares Structure Therapeutics and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
IN8bio	N/A	-96.39%	-80.18%

Earnings and Valuation

This table compares Structure Therapeutics and IN8bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20 million	($0.87)	-59.47
IN8bio	N/A	N/A	-$19.44 million	($2.61)	-0.52

Structure Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Structure Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager
platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.